Global Oncology & Cancer Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oncology & Cancer Drugs Market Research Report 2024
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified. When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
According to Mr Accuracy reports’s new survey, global Oncology & Cancer Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oncology & Cancer Drugs market research.
Key manufacturers engaged in the Oncology & Cancer Drugs industry include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Oncology & Cancer Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Oncology & Cancer Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oncology & Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oncology & Cancer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Oncology & Cancer Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oncology & Cancer Drugs market research.
Key manufacturers engaged in the Oncology & Cancer Drugs industry include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Oncology & Cancer Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Oncology & Cancer Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oncology & Cancer Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oncology & Cancer Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices